Key result
Patients with systemic lupus erythematosus had a higher prevalence of the atherogenic LDL phenotype B compared to healthy controls (52% vs 20%).
Why the study?
Do patients with systemic lupus erythematosus have a higher prevalence of small dense LDL cholesterol particles compared to healthy controls?
Case-Control (n=100)
Do patients with systemic lupus erythematosus have a higher prevalence of small dense LDL cholesterol particles compared to healthy controls?
Absolute Event Rate: 52% vs 20%
Patients with SLE have a significantly higher prevalence of the atherogenic small dense LDL phenotype, which may contribute to their increased risk of coronary heart disease.
May contribute to excess CHD risk in SLE; hypothesis-generating and should not yet alter clinical lipid management.
BACKGROUND: Patients with systemic lupus erythematosus (SLE) are 5-8 times more likely to develop coronary heart disease than the general population. The aim of this study was to find out the prevalence of the small dense low-density lipoprotein (LDL) cholesterol particle in patients with SLE. METHODS: We recruited 50 consecutive patients with SLE who had no evidence of hypertension or renal failure. Fifty age- and gender-matched healthy controls were also recruited. We measured serum lipid levels and LDL particle diameters by gradient gel electrophoresis in both patients and controls. RESULTS: Patients with SLE had significant dyslipidemia, characterized by elevated plasma triglycerides, LDL cholesterol, Apoprotein B, triglyceride:high-density (HDL) lipoprotein cholesterol ratio, and decreased plasma concentrations of HDL cholesterol. The LDL particle size in SLE (24.8 ± 1.23 nm) was significantly (P < 0.01) smaller than that in controls (26.1 ± 1.31 nm). The prevalence of the LDL phenotype B (the atherogenic phenotype) was 52% in SLE but only 20% in healthy controls. CONCLUSION: We conclude that the high prevalence of small dense LDL in SLE may contribute to the high incidence of coronary heart disease seen in this disorder.
No takes yet. Share an insight, caveat, or question.
Olusoji Olusi (2011) conducted a case-control in Systemic lupus erythematosus (n=100). Systemic lupus erythematosus vs. Healthy controls was evaluated on Prevalence of LDL phenotype B (atherogenic phenotype). Patients with systemic lupus erythematosus had a higher prevalence of the atherogenic LDL phenotype B compared to healthy controls (52% vs 20%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: